Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed 0.03% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, changed 0.03% year-over-year, with the annual reading at $2.9 million for FY2025, 0.03% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.9 million at Phathom Pharmaceuticals, up from $1.7 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $3.7 million in Q2 2023, with the low at $299000.0 in Q4 2022.
  • Average Other Non-Current Assets over 4 years is $2.0 million, with a median of $2.3 million recorded in 2023.
  • Peak annual rise in Other Non-Current Assets hit 467.72% in 2024, while the deepest fall reached 40.8% in 2024.
  • Over 4 years, Other Non-Current Assets stood at $299000.0 in 2022, then soared by 465.89% to $1.7 million in 2023, then soared by 69.15% to $2.9 million in 2024, then dropped by 0.03% to $2.9 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.9 million, $1.7 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.